Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway Howard A. Burris III Review Article 03 February 2013 Pages: 829 - 842
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer Kyung-Hun LeeHye Jung ChangTae-You Kim Original Article 13 January 2013 Pages: 843 - 851
Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer Tatsuya MiyazakiMakoto SohdaHiroyuki Kuwano Original Article 10 January 2013 Pages: 853 - 857
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung Hidemi KiyotaIsamu OkamotoKazuhiko Nakagawa Original Article 20 January 2013 Pages: 859 - 865
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo Pradip DeNandini DeyDonald L. Durden Original Article 25 January 2013 Pages: 867 - 881
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer Emmanuel S. AntonarakisElisabeth I. HeathMichael A. Carducci Original Article 13 January 2013 Pages: 883 - 892
Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Gangjun DuYingming YangHouyun Zhang Original Article 26 January 2013 Pages: 893 - 904
A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus Jialei WangJianhua ChangWei Peng Original Article 01 February 2013 Pages: 905 - 911
All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer Hesham TawfikYousri RostomHesham Elghazaly Original Article 24 January 2013 Pages: 913 - 919
Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term Liqi ChenGuoli LiCaihua Zhang Original Article 25 January 2013 Pages: 921 - 928
The PPARγ agonist pioglitazone crosses the blood–brain barrier and reduces tumor growth in a human xenograft model Christian GrommesJ. Colleen KarloGary E. Landreth Original Article 29 January 2013 Pages: 929 - 936
Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination Kunitoshi ShigeyasuShunsuke KagawaToshiyoshi Fujiwara Original Article 25 January 2013 Pages: 937 - 943
Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma Hye Jin KangSeung-Sook LeeSang Moo Lim Original Article 31 January 2013 Pages: 945 - 953
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases Apostolia M. TsimberidouYang YeRobert A. Wolff Original Article 03 February 2013 Pages: 955 - 963
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1–7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy Huyen PhamBenjamin M. SchwartzGere S. diZerega Original Article 31 January 2013 Pages: 965 - 972
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer Takashi SasakiHiroyuki IsayamaKazuhiko Koike Original Article 26 January 2013 Pages: 973 - 979
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas Sook Ryun ParkGiovanna SperanzaShivaani Kummar Original Article 13 February 2013 Pages: 981 - 990
A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors Yutaka FujiwaraYuichi AndoHironobu Minami Original Article 01 February 2013 Pages: 991 - 998
Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter Christina CherianSita Kugel DesmoulinLarry H. Matherly Original Article 15 February 2013 Pages: 999 - 1011
A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens C. FaivreD. BarbolosiN. André Original Article 07 February 2013 Pages: 1013 - 1019
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies Jane KendrewRajesh OdedraJuliane M. Jürgensmeier Original Article 26 January 2013 Pages: 1021 - 1032
Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract Joo Hee ParkSoon Wook LeeKyong Hwa Park Original Article 01 February 2013 Pages: 1033 - 1039
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors Shahneen K. SandhuKyri PapadopoulosAnthony W. Tolcher Original Article 06 February 2013 Pages: 1041 - 1050
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer G. BisagniA. MusolinoC. Boni Original Article 03 February 2013 Pages: 1051 - 1057
Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma Hiroyuki HaradaKen OmuraSatoru Shintani Original Article Open access 03 February 2013 Pages: 1059 - 1064
Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer Dong-sheng ZhangDe-shen WangRui-hua Xu Original Article 13 March 2013 Pages: 1065 - 1072
Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy Shizhi WangLulu ChenZhengdong Zhang Original Article 20 February 2013 Pages: 1073 - 1082
Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors Nianhang ChenSant P. ChawlaSunil Sharma Clinical Trial Report 12 February 2013 Pages: 1083 - 1094
Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells Hemant KulkarniHarald H. H. GöringMelanie A. Carless Short Communication 19 February 2013 Pages: 1095 - 1100
Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors Shailendra Kapoor Letter to the Editor 06 February 2013 Pages: 1101 - 1101
Reply to: Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors Ching-Yuan ChengShur-Hueih CherngGwo-Tarng Sheu Letter to the Editor 03 February 2013 Pages: 1103 - 1104
Erratum to: Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic-phase chronic myeloid leukemia Poe-Hirr HsyuDiane R. MouldMichael Amantea Erratum 27 February 2013 Pages: 1105 - 1106
